SLNO Relative Valuation
SLNO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SLNO is overvalued; if below, it's undervalued.
Historical Valuation
Soleno Therapeutics Inc (SLNO) is now in the Fair zone, suggesting that its current forward PS ratio of 29.61 is considered Fairly compared with the five-year average of -9.67. The fair price of Soleno Therapeutics Inc (SLNO) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：87.20
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
18.31
P/B
Median3y
8.25
Median5y
5.90
-1.98
FCF Yield
Median3y
-49.86
Median5y
-50.05
Competitors Valuation Multiple
The average P/S ratio for SLNO's competitors is 19.99, providing a benchmark for relative valuation. Soleno Therapeutics Inc Corp (SLNO) exhibits a P/S ratio of 29.61, which is 48.13% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Soleno Therapeutics Inc (SLNO) currently overvalued or undervalued?
What is Soleno Therapeutics Inc (SLNO) fair value?
How does SLNO's valuation metrics compare to the industry average?
What is the current P/B ratio for Soleno Therapeutics Inc (SLNO) as of Jul 19 2025?
What is the current FCF Yield for Soleno Therapeutics Inc (SLNO) as of Jul 19 2025?
What is the current Forward P/E ratio for Soleno Therapeutics Inc (SLNO) as of Jul 19 2025?